THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA

MAHAMAYA LIFESCIENCES LIMITED

Corporate Identification Number: U24233DL2002PLC115261

Our Company was originally incorporated as a private limited Company under the name of "Mahamaya Life Sciences Private Limited" under the provisions of the Companies Act, 1956 and certificate of incorporation was issued by the Assistant Registrar of Companies, NCT of Delhi & Haryana, on May 07, 2002. Further, our Company name was changed from "Mahamaya Life Sciences Private Limited" to "Mahamaya Lifesciences Private Limited" and a fresh certificate of Incorporation dated February 15, 2016 was issued by the Registrar of Companies, Delhi. Moreover, a special resolution was passed at the Extra-Ordinary General Meeting of our Company held on October 29, 2024 for conversion of our Company into a public limited Company and the name of our Company was changed from "Mahamaya Lifesciences Private Limited" to "Mahamaya Lifesciences Limited". A fresh certificate of incorporation consequent to change of name was issued by the Registrar of Companies, Delhi on November 19, 2024. The Corporate Identity Number of our Company into a public limited Company and the name of our Company was changed from "Mahamaya Lifesciences Private Limited" to "Mahamaya Lifesciences Limited". A fresh certificate of incorporation consequent to change of name was issued by the Registrar of Companies, Delhi on November 19, 2024. The Corporate Identity Number of our Company is U24233DL2002PIC115261.

The company specializes in the manufacturing of pesticide formulations and supply bulk formulations catering to both Indian agrochemical companies, as well as multinational corporations (MNCs). We began our journey by focusing on import and registration of vital pesticide molecules (Technical) that were not produced domestically in India. We imported these molecules after lot of product research and worked on registering them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. After successful registration we marketed these molecules both as technical and as value added end use formulations for both domestic manufacturers and MNCs.

Summary description of key risk factor based on materiality:

• Our top ten customers constituted 71.35%, 76.26%, 83.14% and 71.12% of our sales for the period ended June 30, 2025 and for the financial year ended March 31, 2025, March 31, 2024, March 31, 2023 respectively. Absence of large number of customers, dependence on few customers and creating a customer concentration risk which may have an adverse impact on our business operations and financial performance.

• Our Company has not entered into long-term agreements with our customers for purchasing our products nor for the supply of raw materials with our suppliers. We are subject to uncertainties in demand/supply and there is no assurance that these customers and suppliers will continue to purchase our products or sell raw materials to us or that they will not scale down their orders. This could impact the business and financial performance of our Company.

• Raw materials constitute a significant percentage of our Company's total expenses. Any increase in prices and any decrease in the supply would materially adversely affect our Company's business.

• We are required to obtain and/or renew certain registrations from the CIB&RC for our products manufactured in India. We also register our products in overseas jurisdictions through our International Distribution Partners to enable exports to such countries. Any failure to successfully register our products in India or in the international markets may affect our results of operations and financial condition.

• We have complied with the timely filing requirement for statutory dues but have faced delays in payment due to technical issue.

• We are party to certain litigation and claims. These legal proceedings are pending at different levels of adjudication before various forums and regulatory authorities. Any adverse decision may make us liable to liabilities/penalties and may adversely affect our reputation, business, and financial status.

• Perception of non-compliance due to non-reflection of TDS payment on the TRACES Portal

• We may not be able to avail funding from banks or financial institution for our future working capital requirements. The failure to obtain such financing may adversely affect our ability to grow and our future profitability.

• The Objects of the Offer for which funds are being raised have not been appraised by any bank or financial institution. The deployment of funds is entirely at the discretion of our management and as per the details mentioned in the section titled "Objects of the Offer". Any revision in the estimates may require us to reschedule our expenditure and may have a bearing on our expected revenues and earnings.

• Our Company had negative cash flows, details of which are given below. Sustained negative cash flow could adversely impact our business, financial condition and results of operations.

For further details please refer chapter titled 'Risk Factors' beginning on page no. 31 of the Prospectus.

• The Merchant Banker associated with the Offer has handled 3 Public Issues in the past 3 financial years, out of which nil Issue closed below Issue Price on listing date.

• The average cost of acquisition of Equity Shares by the Individual Promoters is:

• P/E ratio based on the Basic and Diluted EPS, as restated for Financial year 2024-25 for the Company is 15.00 at cap price

• Weighted Average Return on Networth for Financial Year 2024-25, 2023-24 and 2022-23 is 23.36%

• The Weighted average cost of acquisition of all Equity Shares transacted in the last eighteen months, one year and three years immediately preceding the date of the Prospectus is set forth below:

This Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 229 of the SEBI ICDR Regulations and in compliance with Regulation 253 of the SEBI ICDR Regulations, wherein not more than 50.00% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company and Selling Shareholder, in consultation with the Book Running Lead Manager, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price Further, 5.00% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders, including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5.00% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15.00% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors wherein (a) one third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than two lots and up to such lots equivalent to not more than Rs. 10 lakhs; (b) two third of the portion available to Non-Institutional Investors shall be reserved for Applicants with Application size of more than Rs.10 lakhs; and (c) any unsubscribe portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to Applicants in the other sub-category of Non- Institutional Investors; and not less than 35.00% of the Net Offer shall be available for allocation to Individual Investors, who applies for minimum application size, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders are required to participate in the Offer by mandatorily utilizing the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA Account (as defined hereinafter) in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. For details, see "Offer Procedure" on page number 316 of this Prospectus

The Company received 8 Anchor Investor Application Forms from 8 Anchor Investors (including Nil mutual funds through Nil Mutual Fund schemes) for 2,031,600 Equity Shares. Such 8 Anchor Investors through 7 Anchor Investor Application Forms were allocated 17,52,000 Equity Shares at a price of Rs.114/- per Equity Share under the Anchor Investor Portion, aggregating to Rs. 199,728,000/-

The Offer was subscribed to the extent of 1.47 times (including the Anchor Investor Portion) as per the bid books of BSE (the "Bid Files") after removing multiple and duplicate bids & Bid not bank cases. The Details of the Applications received from various categories (before technical rejection) are as under:

The Basis of Allotment was finalized in consultation with the Designated Stock Exchange - BSE on November 14, 2025

1) Allocation to Individual Investors (After Technical Rejections): The Basis of Allotment to the Individual Investors, who have bid at or above the Offer Price of Rs. 114.00 per equity shares, was finalized in consultation with BSE. The category was subscribed by 1.00583 times i.e. for 20,71,200 Equity Shares. Total number of shares allotted in this category is 20,59,200 Equity Shares to 858 successful applicants. The category wise details of the Basis of Allotment are as under:

The Basis of Allotment to the Non-Institutional Investors, who have bid at or above the Offer Price of Rs.114 00 per equity shares, was finalized in consultation with BSE. The category was subscribed by 0.87755 times i.e. for 2,58,000 Equity Shares. Total number of shares allotted in this category is 2,58,000 Equity Shares to 62 successful applicants. The category wise details of the Basis of Allotment are as under:

Note: Unsubscribed portion of 36,000 Equity shares have been spilled over to NIB Above 10 Lakhs Category.

The Basis of Allotment to the Non-Institutional Investors (more than Rs.10 Lakhs), who have bid at or above Offer Price of Rs. 114.00 per Equity Share or above, was finalized in consultation with BSE. This category has been subscribed to the extent of 4.71346 times i.e. for 29,41,200 Equity Shares. Total number of shares allotted in this category is 6,24,000 (i.e. Includes spilled over of 36,000 Equity Shares from NIB Above 2 Lakhs and upto 10 Lakhs Category) Equity Shares to 82 successful applicants. The category wise details of the Basis of Allotment are as under:

Please Note: 1 additional lot of 1200 shares have been allocated to Categories 9600,19200,44400,87600 in the ratio of 34:55,1:2,1:2,57

4) Allocation to QIBs excluding Anchor Investors (Alter Technical Rejections): The Basis of Allotment to the QIBs excluding Anchor Investors, who have bid at or above the Offer Price of Rs.114.00 per equity shares, was finalized in consultation with BSE. The category was subscribed by 1.19184 times i.e. for 1,401,600 Equity Shares. Total number of shares allotted in this category is 1,176,000 Equity Shares to 9 successful applicants. The category wise details of the Basis of Allotment are as under:

5) Allocation to Anchor Investors (After Technical Rejections & Withdrawal): The Company in consultation with the BRLM has allotted 17,52,000 Equity Shares to 7 Anchor Investors at Anchor Investor Offer Price of Rs.114.00 per equity shares in accordance with the SEBI ICDR Regulations. The category wise details of the Basis of Allotment are as under:

6) Allocation to Market Maker (After Technical Rejections):

The Basis of Allotment to Market Maker, who have bid at Offer Price of Rs.114.00 per equity shares or above, was finalized in consultation with BSE. The category was subscribed by 1.00000 times i.e. for 3,09,600 shares the total number of shares allotted in this category is 3,09,600 Equity Shares to 1 successful applicant. The category wise details of the Basis of Allotment are as under:

The Board of Directors of the Company at its meeting held on November 14, 2025 has approved the Basis of Allocation of Equity Shares as approved by the Designated Stock Exchange viz. BSE and has authorized the corporate action for issue of the Equity Shares to various successful applicants. The CAN-cum-allotment advices and/or notices will forward to the email id's and address of the Applicants as registered with the depositories / as filled in the application form on or before November 14, 2025. Further, the instructions to Self Certified Syndicate Banks for unblocking the amount will process on or prior to November 14, 2025. In case the same is not received within ten days, investors may contact at the address given below. The Equity Shares allocated to successful applicants are being credited to their beneficiary accounts subject to validation of the account details with the depositories concerned. The Company is taking steps to get the Equity Shares admitted for trading on the SME platform of BSE Ltd within three working days from the date of the closure of the issue.

Note: All capitalized terms used and not defined herein shall have the respective meanings assigned to them in the Prospectus dated November 14,2025 ("Prospectus") filed with Registrar of Companies, Delhi.

The details of the allotment made would also be hosted on the website of the Registrar to the Issue, KFin Technologies Limited at www.kfintech.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/ Sole applicants, serial number of the Bid cum Application Form, PAN, Client ID, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:

KFin Technologies Limited

Address: Selenium Tower B, Plot No-31 & 32, Financial District, Nanakramguda, Serilingampally Hyderabad Rangareddi TG 500032

Tel No.: +91-40-67162222/18003094001

Fax No.: +91-40-6716 1563

E-mail: compliance.corp@kfintech.com/mahamaya.ipo@kfintech.com

Investor Grievance Email: einward.ris@kfintech.com

Website: www.kfintech.com

Contact Person: Mr. M. Murli Krishna

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF MAHAMAYA LIFESCIENCES LIMITED.

Disclaimer: Mahamaya Lifesciences Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public otter of its Equity Shares. The Prospectus dated November 14, 2025 has been filed with the Registrar of Companies, Delhi. The Prospectus is available on the website of BSE Limited at www.bseindia.com, on the website of the BRLM at https://www.oneviewadvisors.com/ and on the website of the Company at https://www.mahamayalifesciences.com/. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, please see the section entitled "Risk Factors" on page 31 of the Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state secures laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. Accordingly, the Equity Shares are being issued and sold outside the United States in ‘offshore transactions' in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such offers and sales are made.